Advice
Following a resubmission
maraviroc (Celsentri®) is not recommended for use within NHS Scotland in combination with other antiretroviral medicinal products, for treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable.
When added to optimised background therapy, maraviroc was associated with a significant reduction in viral load compared with addition of placebo in heavily pre-treated patients. However, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice63KB (PDF)
Medicine details
- Medicine name:
- maraviroc (Celsentri)
- SMC ID:
- 458/08
- Indication:
- For treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Infections
- Submission type
- Resubmission
- Status
- Not recommended
- Date advice published
- 13 October 2008